Binh Pham, DO, MPH, MS
Abstract
Topiramate is a widely used anticonvulsant with a multimodal neuropharmacologic profile and a well-recognized potential to produce cognitive adverse effects. Reported impairments include disturbances in attention, processing speed, memory, verbal fluency, and language, with greater effects observed in some studies at higher doses. Language-related dysfunction, particularly word-finding difficulty and reduced verbal fluency, appears to be among the most consistently described cognitive manifestations. The mechanisms underlying these effects remain incompletely defined. Topiramate modulates several pathways involved in neuronal excitability, including voltage-gated sodium channels, gamma-aminobutyric acid (GABA)-mediated neurotransmission, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate glutamate receptors, carbonic anhydrase, and possibly voltage-gated calcium channels. Experimental studies support effects on both inhibitory and excitatory neurotransmission, while functional imaging and exposure-response studies provide preliminary evidence linking topiramate treatment with altered cognitive processing and language-related network activity. Cognitive effects appear to be influenced by dose and individual susceptibility and may improve following dose reduction or discontinuation. This focused Mini Review summarizes the neuropharmacology of topiramate, examines its principal cognitive effects, and evaluates current evidence regarding possible mechanisms, reversibility, and clinical implications. Overall, the cognitive phenotype appears multifactorial, exposure related, and at least partly reversible, although direct links between individual molecular targets and specific cognitive deficits have not been established.
Keywords: Topiramate; Cognition; Neuropharmacology; Verbal fluency; GABA; Glutamate.